Mean cost per number needed to treat with tocilizumab plus methotrexate versus abatacept plus methotrexate in the treatment of rheumatoid arthritis in patients previously treated with methotrexate

References

• GibofskyAEpidemiology, pathophysiology, and diagnosis of rheumatoid arthritis: a synopsisAm J Manag Care2014207 SupplS128S13525180621
   PubMed Web of Science ®Google Scholar
• GibofskyAOverview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritisAm J Manag Care20121813 SupplS295S30223327517
   PubMedGoogle Scholar
• SinghJAFurstDEBharatA2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisArthritis Care Res2012645625639
   PubMed Web of Science ®Google Scholar
• KvienTKEpidemiology and burden of illness of rheumatoid arthritisPharmacoeconomics200422Suppl 1112
   PubMed Web of Science ®Google Scholar
• De MariaANRelative risk of cardiovascular events in patients with rheumatoid arthritisAm J Cardiol2002896A33D38D
   Web of Science ®Google Scholar
• LubeckDPPatient-reported outcomes and their role in the assessment of rheumatoid arthritisPharmacoeconomics200422Suppl 1273815157002
   PubMed Web of Science ®Google Scholar
• CerraCRavasioRPolcaroFIl costo dell’Artrite Reumatoide: l’esperienza dell’ASL della Provincia di PaviaGiornale Italiano di Health Technol Assess200923111117
   Google Scholar
• ShichikawaKInoueKHirotaSChanges in the incidence and prevalence of rheumatoid arthritis in Kamitonda. Wakayama, Japan. 1965–1996Ann Rheum Dis19995875175610577961
   PubMed Web of Science ®Google Scholar
• CimminoMAParisiAMoggianaGPrevalence of rheumatoid arthritis in Italy: the Chiavari studyAnn Rheum Dis1998573153189741317
   PubMed Web of Science ®Google Scholar
• NellVPMacholdKPEbrelGBenefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritisRheumatology20044390691415113999
   PubMed Web of Science ®Google Scholar
• EmeryPBreedveldFCDougadosMEarly referral recommendation for newly diagnosed rheumatoid arthritis: evidence-based development of a clinical guideAnn Rheum Dis20026129029711874828
   PubMed Web of Science ®Google Scholar
• KuekAHazlemanBLÖstorAJKImmune mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolutionPostgrad Med J20078325126017403952
   PubMed Web of Science ®Google Scholar
• LeeDMWeinblattMERheumatoid arthritisLancet200135890391111567728
   PubMed Web of Science ®Google Scholar
• CaporaliRContiFAliverniniSRecommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. EfficacyClin Exp Rheumatol201129Suppl 66S7S1421906423
   PubMed Web of Science ®Google Scholar
• ThwaitesCFinneyARheumatoid arthritis. 2: exploring treatment options to achieve early control and remissionNurs Times2010106101820
   Google Scholar
• National Institute for Health and Clinical ExcellenceRheumatoid arthritis (CG79): full guidelineLondon. UKNICE2009 Available from: http://guidance.nice.org.uk/CG79/GuidanceAccessed March 1, 2017
   Google Scholar
• ContiFScrivoRIl follow-up del paziente con artrite reumatoide di lunga Durata. [The follow - up of the patient with Rheumatoid Arthritis long duration]Focus Anno XIV. N 1. Febbraio 2011 Italian. Available from: https://elearning2.uniroma1.it/pluginfile.php/114873/mod_resource/content/1/Artrite%20reumatoide.pdfAccessed March 1, 2017
   Google Scholar
• AletahaDSmolenJSThe simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritisClin Exp Rheumatol200523Suppl 39S100S10816273793
   PubMed Web of Science ®Google Scholar
• PrevooMLvan‘t HofMAKuperHHModified disease activity scores that include twenty eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis Rheum19953844487818570
   PubMed Web of Science ®Google Scholar
• NICE GuidanceAdalimumab, etanercept, Inflfliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. Technology appraisal guidance Published: 26 January 2016. Available from: http://nice.org.uk/guidance/ta375Accessed March 2017
   Google Scholar
• KristensenLEChristensenRBliddalHGeborekPDanneskiold-SamsøeBSaxneTThe number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature reviewScand J Rheumatol200736641141718092260
   PubMed Web of Science ®Google Scholar
• BarraLPopeJEPayneMReal-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaireJ Rheumatol20093671421142819487267
   PubMed Web of Science ®Google Scholar
• Gruppo di lavoro AIES (coordinato da G Fattore)Proposta di linee guida per la valutazione economica degli interventi sanitari in Italia. Proposed guidelines for the economic evaluation of health interventions in ItalyPharmacoEconomics20091128393 Italian
   Google Scholar
• National Institute for Health and Care ExcellenceGuide to the methods of technology appraisal2013 Available from: http://www.nice.org.uk/aboutnice/howwework/devnicetech/guidetothemethodsoftechnologyappraisal.jspAccessed October 2014
   Google Scholar
• Canadian Agency for Drugs and Technologies in HealthGuidelines for the Economic Evaluation of Health Technologies: Canada3rd Edition2006 Available from: https://www.cadth.ca/media/pdf/186_EconomicGuidelines_e.pdfAccessed March 2017
   Google Scholar
• BurmesterGRRubbert-RothACantagrelAA randomized, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)Ann Rheum Dis2014731697423904473
   PubMed Web of Science ®Google Scholar
• GenoveseMCCovarrubiasALeonGSubcutaneous abatacept versus intravenous abatacept: a phase IIIb non inferiority study in patients with an inadequate response to methotrexateArthritis Rheum201163102854286421618201
   PubMed Web of Science ®Google Scholar
• Prestazioni di assistenza specialistica ambulatoriale. [Outpatient specialist services]Supplemento ordinario n. 8 alla Gazzetta Ufficiale. Serie generale n. 23 Available from: http://www.crob.it/crob/files/docs/10/63/33/DOCUMENT_FILE_106333.pdfAccessed January 28, 2013 Italian
   Google Scholar
• BatticciottoARavasioRRivaMSarzi-PuttiniPEfficacy and treatment costs of monotherapy with bDMARDs in the treatment of rheumatoid arthritis in patients intolerant to or inappropriate to continue treatment with methotrexateAdv Ther20163381360137327376373
   PubMed Web of Science ®Google Scholar
• LiuYWuEQBensimonAGCost per responder associated with biologic therapies for Crohn’s disease, psoriasis, and rheumatoid arthritisAdv Ther201229762063422843208
   PubMed Web of Science ®Google Scholar
• SinghJAWellsGAChristensenRAdverse effects of biologics: a network meta-analysis and Cochrane overviewCochrane Database Syst Rev20112CD008794
   PubMed Web of Science ®Google Scholar
• PierreisnardAIssaNBarnetcheTRichezCSchaeverbekeTMeta-analysis of clinical and radiological efficacy of biologics in rheumatoid arthritis patients naive or inadequately responsive to methotrexateJoint Bone Spine201380438639223141718
   PubMed Web of Science ®Google Scholar